Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF

被引：0
|
作者：
Pozniak, A. [1 ]
Maggiolo, F. [2 ]
Podzamczer, D. [3 ]
Yazdanpanah, Y. [4 ]
Gupta, S. [5 ]
Esser, S. [6 ]
Mounzer, K. [7 ]
Grossberg, R. [8 ]
Post, F. [9 ]
Huang, H. [10 ]
Acosta, R. [10 ]
Baeten, J. [10 ]
Hindman, J. [10 ]
Martin, H. [10 ]
Orkin, C. [11 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy
[3] Hosp Univ Bellvitge, Lhospitalet De Llobregat, Spain
[4] Hop Bichat Claude Bernard, AP HP, Paris, France
[5] Indiana Univ, Indianapolis, IN 46204 USA
[6] Univ Hosp Essen, Essen, Germany
[7] Univ Penn, Philadelphia FIGHT Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Albert Einstein Coll Med, Bronx, NY 10467 USA
[9] Kings Coll Hosp NHS Fdn Trust, Kings Coll Hosp, London, England
[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[11] Queen Mary Univ London, London, England
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/68
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [41] Characteristics and real-world medication persistence of people living with HIV treated with DTG/3TC or BIC/FTC/TAF: a hospital claims database study in Japan
    Kanamori, Rie
    Aoki, Nozomi
    Kanazawa, Akio
    Nakamoto, Daisuke
    Yuda, Mayumi
    Makino, Nao
    Ohata, Emi
    Fukui, Nobuyuki
    Mori, Hirotake
    Yokokawa, Hirohide
    Naito, Toshio
    FRONTIERS IN MEDICINE, 2024, 11
  • [42] STRIIVING: switching to abacavir/dolutegravir/lamivudine fixed dose combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression at week 48
    Lake, J. E.
    Trottier, B.
    Garcia-Diaz, J.
    Edelstein, H.
    Kumar, P.
    Bredeek, U. F.
    Loutfy, M.
    Brennan, C.
    Koteff, J.
    Wynne, B.
    Hopking, J.
    Aboud, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [43] Changes in dynamic platelet function when switching from ABC/3TC to TAF/FTC: GS-US-311-1717 Platelet Substudy
    McGettrick, P. M. C.
    Tinago, W.
    Dunne, E.
    Maughan, R.
    Garcia-Leon, A.
    Alvarez-Barco, E.
    Das, M.
    Rhee, M.
    Kenny, D.
    Mallon, P. W. G.
    ANTIVIRAL THERAPY, 2018, 23 : A49 - A49
  • [44] Increase in bone mineral density and weight in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG
    Samarawickrama, A.
    Hamzah, L.
    Ibrahim, F.
    Ainsworth, J.
    Fox, J.
    Gilleece, Y.
    Hemat, N.
    Johnson, M.
    Kegg, S.
    Orkin, C.
    Prime, K.
    Waters, L.
    Barbini, B.
    Campbell, L.
    Post, F.
    HIV MEDICINE, 2020, 21 : 13 - 13
  • [45] Durable efficacy of switching from a three-/four-drug tenofovir alafenamide (TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196
    De Wit, S.
    Bonnet, F.
    Osiyemi, O.
    Bisshop, F.
    Olalla, J.
    Routy, J.
    Wyen, C.
    Moodley, R.
    Pappa, K.
    Wang, R.
    Oyee, J.
    Saggu, P.
    Letang, E.
    Wynne, B.
    Jones, B.
    Smith, K.
    Ait-Khaled, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 12 - 13
  • [46] Correction to: Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study
    Chun-Yuan Lee
    Chen-Hsiang Lee
    Hung-Jen Tang
    Hung-Chin Tsai
    Chen-Hsun Yang
    Yi-Pei Lin
    Sheng-Fan Wang
    Po-Liang Lu
    Infectious Diseases and Therapy, 2023, 12 : 863 - 869
  • [47] Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people with human immunodeficiency virus who start DTG/ABC/3TC compared to BIC/FTC/TAF at 48-week follow-up
    Diaz, Ana Luz Cano
    Gonzalez, Salma Triana
    Velazquez, Gloria Elizabeth Salinas
    Marin, Jose Antonio Mata
    Martinez, Jesus Enrique Gaytan
    Mauss, Stefan
    INTERNATIONAL JOURNAL OF STD & AIDS, 2025, 36 (01) : 36 - 41
  • [48] COST EFFECTIVENESS ANALYSIS OF DTG/3TC VERSUS EVG/C/TARIFTC AND BIC/TAF/FTC FOR HIV-I INFECTION MANAGEMENT IN TREATMENT-NAIVE PATIENTS IN CHINA
    Fan, L.
    Tang, Z.
    Anderson, S. J.
    Evitt, L.
    Jacob, I
    Shiri, T.
    Turner, M.
    Tewary, A.
    VALUE IN HEALTH, 2022, 25 (12) : S132 - S133
  • [49] Evaluation of T-cell immunosenescence markers in virologically suppressed people living with HIV aged over 60 years on BIC/FTC/TAF or DTG/3TC: the Collateral study
    Vassallo, Matteo
    Ticchioni, Michel
    Chirio, David
    Sadou, Ami
    Cua, Eric
    Ceppi, Carole
    Ferrando, Sara
    Naqvi, Alissya
    Prouvost-Keller, Bernard
    Mangin-Ratana, Sommani
    Ameil, Leslie
    Godemert, Maeva
    Carles, Michel
    Durant, Jacques
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 248 - 249
  • [50] Switching to DTG+3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study)
    van Wyk, J.
    Ajana, F.
    Bisshop, F.
    De Wit, S.
    Osiyemi, Y.
    Portilla, J.
    Routy, J. -P.
    Wyen, C.
    Ait-Khaled, M.
    Nascimento, M.
    Pappa, K.
    Wang, R.
    Wright, J.
    Tenorio, A. -R.
    Wynne, B.
    Aboud, M.
    Gartland, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 102 - 103
12345